Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study

Table 3 Univariate analysis of prognostic factors for progression-free survival and overall survival

Variables	No. of patients	5-year PFS (95% CI)	P value	5-year OS (95% CI)	P value
Age at diagnosis (years)
<60	55	54.0 ± 8.1	0.943	61.6 ± 7.8	0.616
≥60	13	58.2 ± 17.0		57.3 ± 17.0
Ann Arbor stage
I-II	45	61.3 ± 9.2	0.038	70.7 ± 8.0	0.010
III-IV	23	38.5 ± 11.9		35.1 ± 13.8
B symptoms
No	63	54.3 ± 7.8	0.288	61.8 ± 7.4	0.088
Yes	5	50.0 ± 25.0		50.0 ± 25.0
ECOG performance status
0-1	63	55.8 ± 7.9	0.016	63.4 ± 7.4	0.015
2-3	5	40.0 ± 21.9		25.0 ± 21.7
LDH level
Normal	36	68.3 ± 11.2	0.007	71.0 ± 8.9	0.049
Elevated	26	36.1 ± 11.8		40.1 ± 12.3
No. of involved extranodal organ
OED	49	64.9 ± 8.9	0.001	74.3 ± 7.6	<0.001
MED	19	27.5 ± 11.4		24.5 ± 13.0
IPI
Low to low-intermediate	50	63.2 ± 9.1	<0.001	69.2 ± 8.1	0.001
High-intermediate to high	16	25.0 ± 12.3		23.6 ± 13.7
Traditional strict criteria
Traditional PBL	43	89.4 ± 5.9	0.008	72.6 ± 8.0	0.008
Traditional SBL	25	61.7 ± 12.8		33.3 ± 13.4
Radiotherapy to the breast
No	47	58.4 ± 8.5	0.777	56.6 ± 9.4	0.477
Yes	21	51.8 ± 12.0		66.7 ± 11.3
Surgery of breast
No	45	53.4 ± 9.6	0.839	58.6 ± 9.7	0.582
Yes	23	57.2 ± 11.5		64.1 ± 10.9
Treatment strategy
<4cycles ± any local modalities	12	28.0 ± 16.4	<0.001	19.3 ± 16.2	<0.001
≥4cycles ± any local modalities	55	58.0 ± 8.3		66.2 ± 7.7
Rituximab use
No	26	56.8 ± 11.3	0.366	60.6 ± 10.3	0.975
Yes	42	53.5 ± 9.5		60.3 ± 10.3

Abbreviations: PFS, progression-free survival; OS, overall survival; CI, confidence interval; ECOG Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PBL, primary breast lymphoma; OED, one extranodal disease in the breast; MED, multiple extranodal disease; IPI, international prognostic index; SBL, secondary breast lymphoma.

ISSN: 1471-2407